SAN ANTONIO — More than half of patients with pretreated HER2-positive advanced or metastatic breast cancer who received the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) had ...
Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study. Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results